By Michael DabaieRedHill Biopharma Ltd. said an analysis showed its oral opaganib reduces mortality by 70% given on top of remdesivir and corticosteroids in severe Covid-19. The company said its prespecified analysis of Phase 2/3 opaganib data in severe Covid-19 patients showed a significant, 70.2% mortality benefit with opaganib by day 42 when given on top of the best available standard-of-care, remdesivir and corticosteroids.

Source: Wall Street Journal February 07, 2022 21:57 UTC